PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSacituzumab govitecan
Trodelvy(sacituzumab govitecan)
Trodelvy (sacituzumab govitecan) is an antibody drug conjugate pharmaceutical. Sacituzumab govitecan was first approved as Trodelvy on 2020-04-22. It is used to treat triple negative breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms and triple negative breast neoplasms. The pharmaceutical is active against tumor-associated calcium signal transducer 2.
Download report
Favorite
FDA Novel Drug Approvals 2020
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Trodelvy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Sacituzumab govitecan
Tradename
Proper name
Company
Number
Date
Products
Trodelvysacituzumab govitecan-hziyGilead SciencesN-761115 RX2020-04-22
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
trodelvyBiologic Licensing Application2025-03-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
triple negative breast neoplasms—D064726—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
— L01FX17: Sacituzumab govitecan
HCPCS
Code
Description
J9317
Injection, sacituzumab govitecan-hziy, 2.5 mg
Clinical
Clinical Trials
162 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Triple negative breast neoplasmsD064726——123471549
NeoplasmsD009369—C801013—1119
Neoplasm metastasisD009362EFO_0009708—36—1111
Meningeal carcinomatosisD055756EFO_1001012—11—1—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5016448—1470
Non-small-cell lung carcinomaD002289——4113——15
Urinary bladder neoplasmsD001749—C67681—112
Transitional cell carcinomaD002295——472——10
CarcinomaD002277—C80.0361——9
Urologic neoplasmsD014571—C64-C68462——8
Endometrial neoplasmsD016889EFO_0004230—231——4
Colorectal neoplasmsD015179——121——3
Lung diseasesD008171EFO_0003818J98.4——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Brain neoplasmsD001932EFO_0003833C7114——27
Lung neoplasmsD008175—C34.9035———7
Invasive hydatidiform moleD002820—D39.224———6
Squamous cell carcinoma of head and neckD000077195——14———4
GlioblastomaD005909EFO_0000515—22———3
Small cell lung carcinomaD055752——23———3
Ovarian epithelial carcinomaD000077216——23———3
Ovarian neoplasmsD010051EFO_0003893C5623———3
Squamous cell carcinomaD002294———3———3
Salivary gland neoplasmsD012468EFO_0003826D11—3———3
Show 39 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver failureD017093—K72.91————1
Gastrointestinal neoplasmsD005770—C26.91————1
Biliary tract neoplasmsD001661—C24.91————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SepsisD018805EFO_0001420A41.9————11
AgranulocytosisD000380HP_0012234D70————11
Opportunistic infectionsD009894——————11
Treatment outcomeD016896——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSacituzumab govitecan
INNsacituzumab govitecan
Description
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.
Classification
Antibody
Drug classmonoclonal antibodies; antineoplastics (camptothecin derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL3545262
ChEBI ID—
PubChem CID—
DrugBankDB12893
UNII IDM9BYU8XDQ6 (ChemIDplus, GSRS)
Target
Agency Approved
TACSTD2
TACSTD2
Organism
Homo sapiens
Gene name
TACSTD2
Gene synonyms
GA733-1, M1S1, TROP2
NCBI Gene ID
4070
Protein name
tumor-associated calcium signal transducer 2
Protein synonyms
40kD glycoprotein, identified by monoclonal antibody GA733, Cell surface glycoprotein Trop-2, cell surface glycoprotein TROP2, epithelial glycoprotein-1, gastrointestinal tumor-associated antigen GA7331, Membrane component chromosome 1 surface marker 1, membrane component, chromosome 1, surface marker 1, Pancreatic carcinoma marker protein GA733-1, pancreatic carcinoma marker protein GA7331, trophoblast cell surface antigen 2
Uniprot ID
Q96QD2
Mouse ortholog
Tacstd2 (56753)
tumor-associated calcium signal transducer 2 (Q8BGV3)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Trodelvy – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 655 documents
View more details
Safety
Black-box Warning
Black-box warning for: Trodelvy
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,679 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use